Skip to main content


We're creating a new version of this page. See preview

  • Review
  • Open Access

Understanding of leukemic stem cells and their clinical implications

Molecular Cancer201716:2

  • Received: 2 October 2016
  • Accepted: 19 December 2016
  • Published:


Since leukemic stem cells (LSCs) or cancer stem cells (CSCs) were found in acute myeloid leukemia (AML) in 1997, extensive studies have been contributed to identification and characterization of such cell populations in various tissues. LSCs are now generally recognized as a heterogeneous cell population that possesses the capacities of self-renewal, proliferation and differentiation. It has been shown that LSCs are regulated by critical surface antigens, microenvironment, intrinsic signaling pathways, and novel molecules such as some ncRNAs. To date, significant progress has been made in understanding of LSCs, leading to the development of numerous LSCs-targeted therapies. Moreover, various novel therapeutic agents targeting LSCs are undergoing clinical trials. Here, we review current knowledge of LSCs, and discuss the potential therapies and their challenges that are being tested in clinical trials for evaluation of their effects on leukemias.


  • Cancer stem cell
  • Leukemia
  • Leukemic stem cell
  • Surface markers
  • BM niche
  • ncRNAs
  • Clinical implications


The existence of CSCs was firstly evidenced in AML [1], and has been now extended to a broad spectrum of solid tumors [28]. In 1994, Dick and colleagues [1] showed that only the leukemic cells expressing the same markers as normal adult hematopoietic stem cells (CD34+CD38) could initiate hematopoietic malignancy, and termed these cells as leukemia-initiating cells, leukemic stem cells (LSCs), or cancer stem cells (CSCs) [1, 9, 10]. Importantly, such cell population possesses the capacities for self-renewal, proliferation and differentiation. Increasing evidence has demonstrated that LSCs are clinically relevant, indicating that therapies targeting LSCs in AML would improve survival outcomes [11].

Conventional anticancer strategy is a combination of surgery, chemotherapy and radiotherapy with allogeneic stem cell transplantation for eligible candidates [1214]. However, elderly patients cannot tolerate such intense regimens, and patients usually face the risk of recurrence, metastasis and drug resistance. It is thought that these therapies predominantly target at a bulk tumor populations but leave CSCs behind. Importantly, these CSCs, with highly expressed ATP-binding cassette (ABC) transporters, have been shown to protect themselves from the attacks from chemotherapeutic agents [1517]. Hence, the inefficient therapy of cancers is mainly attributed to the failure of elimination of the malignant CSCs. It is well recognized that development of CSC-selective therapies is important for treating CSCs-containing cancers [18]. In this review, we discuss the current understanding of LSCs. Also, we summarize various therapeutic agents targeting LSCs that are being studied in clinical trials.

Genetic and epigenetic heterogeneities of LSCs

Leukemias are now viewed as aberrant hematopoietic processes initiated by rare LSCs, which arise from the transformation of hematopoietic stem cells (HSCs) or committed progenitor cells [19]. During the course of malignant transformation, LSCs acquire the capacity of self-renewal, proliferation and differentiation through continuous genetic and epigenetic alteration and clonal diversification. Thus, understanding how genetic and epigenetic heterogeneities develop in different leukemias has become an important area for cancer research. Although CSCs have been found in both leukemia and solid tumors, not all of CSCs in the solid tumors follow the heterogeneity model of LSC.

Increasing investigations using deep genome sequencing have identified many recurrent mutated genes critically implicated in the pathogenesis of human AML [2027]. In 2013, the Cancer Genome Atlas Research Network analyzed the genome of 200 AML patients, and thoroughly defined the recurrent mutations in AML [28]. About 30 genes were identified to be mutated in more than 2% of patients. Remarkably, many of these mutated genes encode proteins that normally function at the epigenetic level, including modifications of DNA cytosine residues and post-translational modifications of histones. In addition, other studies have shown that clonal composition of AMLs appears to be changed quite markedly at both the genetic and epigenetic levels after therapy in relapsed disease [2931].

Interestingly, it has been found that there is a sequential order for the acquisition of these mutations during leukemogenesis. For example, some researchers observed that somatic mutations in epigenetic modifiers that regulate cytosine methylation, such as DNMT3A (DNA methyltransferase 3 alpha), IDH1/2 (isocitrate dehydrogenase 1/2) and TET2 (tet methylcytosine dioxygenase 2), occur early in pre-leukemic HSCs [3234]. However, other somatic mutations in signaling pathways that drive proliferation, such as NPM1 (nucleophosmin 1), FLT3-ITD (internal tandem duplication of the gene FLT3) and KRAS/NRAS (Kirsten rat sarcoma viral oncogene homolog/neuroblastoma rat sarcoma viral oncogene homolog), are later events in AML transformation [35]. These results suggest that disruption of epigenetic patterning is likely an early and prominent event during leukemogenesis.

In order to characterize the expression profile of LSCs in chronic myeloid leukemia (CML), Gerber and colleagues performed genome-wide transcriptome analysis of CML LSCs using exon microarrays [36]. They identified 97 genes that are differentially expressed between CML LSCs and normal HSCs. Further analysis revealed dysregulation of proliferation, differentiation and signaling pathways in CML LSCs. These data may provide potential therapeutic targets unique to CML LSCs.

Surface molecules and microenvironment of LSCs and their clinical implications

Cell surface molecules of LSCs

The AML LSCs were the first reported and best characterized type of CSCs, and they specifically display CD34+CD38 cell surface markers [1, 9, 10]. However, subsequent studies showed that the surface markers of AML LSCs are considerably heterogeneous [3747]. For example, AML LSCs were found not only in Lin/CD38 fractions but also in CD34, Lin+, CD38+, and CD45RA+ fractions [45]. It was also found that true AML LSCs in the CD34+/CD38 fractions, originally described by Bonnet and Dick, were very rare and comprised a hierarchy of cells with different self-renewal potential [46]. In addition, some surface markers of AML LSCs (CD34+, CD38, CD71, and HLA-DR) are shared with normal HSCs, and others (Lin+, CD38+, CD45RA+) are associated with normal committed progenitors [38, 45]. These findings stirred up a debate about whether AML LSCs are derived from the normal HSCs or from the committed progenitor cells. On the other hand, the surface markers of LSCs are heterogeneous, which makes hard for classification of LSCs and even LSCs-targeted treatment in clinics.

Recently, great progress has been made in understanding of LSC surface markers and their clinical applications, especially in AML cases. Firstly, a number of critical surface markers unique to AML LSCs have been identified. For example, it has been revealed that CD90 and CD117 are deficient in AML LSCs [39], while CD123 [42, 48], TIM3 [44, 49], CD47 [50, 51], CD96 [52], CLL-1 [53, 54], and IL-1 receptor accessory protein (IL1RAP) [55] are highly expressed in AML LSCs. Targeting these surface markers is a promising strategy for eradicating AML LSCs. Previous studies have shown that CD123 (IL-3 receptor α chain) was preferentially expressed in the CD34+/CD38 AML cells, as compared with normal HSC samples. Pretreatment of AML cells with anti-CD123 monoclonal antibody 7G3 resulted in decreased engraftment when they were injected into a xenograft model [42, 48]. To date, phase I clinical trials (NCT00401739 and NCT01632852) of using monoclonal antibody targeting CD123 (CSL360 and improved CSL362) [48] have been tested in CD123+ AML patients. Moreover, other monoclonal antibodies targeting CD47 [56, 57], CD96 [52, 58], TIM3 [44, 49] and CLL-1 [54, 59] have also been investigated in pre-clinical models for their ability to eliminate primary AML LSCs. It is worth mentioning that Gemtuzumab Ozogamicin, an anti-CD33 antibody, is the first monoclonal antibody approved by the Food and Drug Administration (FDA) of the USA in 2000 for the treatment of AML, although it may not specifically target LSCs [60].

Secondly, increasing novel therapies are continuously developed to specifically target these surface antigens of LSCs and are undergoing in clinical trials in AML cases. Besides monoclonal antibodies mentioned above [61, 62], these new therapies include both bi-specific and tri-specific antibody fragments [63, 64], immunotoxins [65], chimeric antigen receptor modified T-cells (CAR T-cells) [66], and nano-particles containing surface markers-targeted medication [67]. Notably, DT388IL3 (SL-401) is a recombinant immunotoxin that is created by fusing diphtheria toxin with a ligand targeting IL-3 receptor. At present, DT388IL3 (SL-401) undergoes phase I/II trials (NCT02113982 and NCT02270463) in AML [65] (Table 1).
Table 1

Anti-LSCs agents that are undergoing in AML clinical trials


Name of agents

Property of agents

Stage of clinical trials

Clinical trial identifier


Cell surface antigens




Monoclonal antibody

Phase I


[42, 48]


Monoclonal antibody

Phase I



DT388IL-3 (SL-401)


Phase I/II



Signaling pathways



CAL-101 (Idelalisib)

Inhibitor of PI3K

Phase I





Inhibitor of AKT

Phase I


[184, 185]


Inhibitor of AKT

Phase II


[186, 187]



Inhibitor of mTOR

Phase II




Inhibitor of mTOR

Phase II


[189, 190]



Inhibitor of IκB

Phase I/II


[191, 192]



Inhibitor of β-catenin

Phase I







Antagonist of CXCR4

Phase I/II


[7577, 193]

Microenvironment associated with LSCs

Under normal conditions, HSCs rely on the interactions with the bone marrow (BM) niche, which is critical for their proper function and maintenance [68]. The remodeling of the BM niche is commonly observed in blood malignancies. There is evidence that growth of leukemic cells disrupts the BM niches of normal hematopoietic progenitor cells and creates a microenvironment hospitable for them [69]. Within such microenvironment, LSCs are able to communicate with BM stromal cells through cytokines, chemokines and intracellular signals initiated by cellular adhesion [70, 71]. Importantly, these signals influence the ability of LSCs to self-renew, maintain their quiescence, and prevent apoptosis. In addition, the BM niche provides two distinct microenvironmental zones (the osteoblastic niche and vascular niche) that likely regulate the cycling of LSCs [7173]. Thus, blocking the interactions between LSCs and their microenvironment represents a promising strategy to disrupt LSC homeostasis and restore normal hematopoiesis.

One of such strategies is to dislodge LSCs from their protective BM niche and thus sensitize the LSCs to conventional chemotherapies. It has been demonstrated that LSCs migrate into and remain within the BM niche through the interaction between C-X-C chemokine receptor type 4 (CXCR4) and stromal cell derived factor-1 (SDF-1α), also known as C-X-C motif chemokine 12 (CXCL12) [74]. Recently, manipulating the CXCL12-CXCR4 axis using Plerixafor (AMD3100) in relapsed AML has been reported as a safe strategy in phase I/II clinical trials (NCT00990054 and NCT00822770) [7578]. Additionally, ligation of the adhesion molecules CD44 [79] and vascular cell adhesion molecule 1 (VCAM-1) [80] with their monoclonal antibodies has already been tested in the clinic. Other strategies like altering BM niche remodeling and inflammatory microenvironment, such as targeting pro-inflammatory cytokines tumor necrosis factor alpha (TNFα), IL-1, and IL-6, might be very promising but mainly at pre-clinical stages [81].

Intracellular molecules and signaling of LSCs

Critical signaling pathways involved in regulation of LSCs

LSCs are characterized by limitless self-renewal, proliferation and differentiation. A set of critical genes impact these functional properties through a wide range of cellular pathways and processes, which have been described in detail by many groups [13, 19, 71, 82]. Signaling pathways such as Wnt/β-catenin [8389] and Hedgehog [9092] play important role in regulating self-renewal of LSCs. These signaling pathways are also critically required for the development of normal HSCs [93]. In addition, it is thought that LSCs can evade apoptosis by up-regulating NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) [94, 95] or by down-regulating Fas/CD95 [96]. Here, we review some key signaling pathways involved in the regulation of survival and self-renewal of LSCs.

The well-known Wnt/β-catenin signaling pathway plays fundamental role in maintaining CSC populations. The activation of Wnt/β-catenin pathway leads to the translocation of β-catenin into the nucleus, where it induces the expression of target genes such as c-Myc, c-Jun and cyclin D1 [97101]. Various experiments have demonstrated that Wnt/β-catenin signaling pathway acts as a key regulator in controlling proliferation, survival, and differentiation of hematopoietic cells [99, 102]. Aberrant activation of Wnt/β-catenin signaling pathway has also been found in both AML [8789] and CML [83, 84]. Subsequent studies have shown that Wnt/β-catenin signaling pathway is required for efficient self-renewal of LSCs, indicating that it is an attractive therapeutic strategy to target Wnt/β-catenin signaling in AML and CML [84, 85]. In addition, it has been documented that Wnt signaling pathway and the polycomb-group protein BMI1 (B lymphoma Mo-MLV insertion region 1 homolog) are involved in the expansion of LSCs [103105].

Janus kinase (JAK)/signal transducer and activator of transcription (STAT) and phosphatidylinositide 3-kinase (PI3K)/protein kinase B (AKT) are two crucial signaling pathways that have been implicated in LSC survival and multiple cancer formation. It is well established that malignant transformation of many cell types, especially hematopoietic cells, involves the dysregulation of JAK/STAT and/or PI3K/AKT that regulate cellular proliferation and survival. For example, there is considerable evidence showing that aberrations in these signaling pathways are associated with numerous leukemias. In CML, JAK/STAT/PIM (proviral insertion in murine) and PI3K/AKT/mTOR (mammalian/mechanistic target of rapamycin) pathways are constitutively activated by Bcr-Abl, a non-receptor tyrosine kinase, resulting in uncontrolled cellular proliferation [12, 106108]. Bcr-Abl can also cause tyrosine phosphorylation of suppressors of cytokine signaling 1 and 3 (SOCS-1 and SOCS-3), two potent suppressors of JAK/STAT signaling, and thereby diminish their inhibitory effects on JAK/STAT activation [109]. Interestingly, PI3K mutation and AKT1 (E17K) mutation has been identified in a variety of tumors. AKT1 (E17K) mutant, a constitutively activated form of AKT1, can significantly promote tumorigenesis [110]. In addition, it was observed that other members of the PI3K/AKT/mTOR pathway, such as PTEN (phosphatase and tensin homolog) and mTOR, function in the maintenance of LSCs [111]. Recently, we have shown that there exists a crosstalk between JAK/STAT/PIM and PI3K/AKT/mTOR pathways that converge on eukaryotic translation initiation factor 4B (eIF4B) to regulate the survival of Abl transformants [112, 113].

In brief, increasing evidence has suggested that multiple signaling pathways are involved in the development of LSCs. Profound elucidation of the intricate pathway network in LSCs is significant in understanding of LSCs and designing precise treatment of leukemia through targeting LSCs. Currently, various clinical trials are in process to test the efficacy of agents targeting intracellular proteins and pathways associated with LSCs. For example, clinical studies of the drug CAL-101, an inhibitor of PI3K, showed remarkable success in chronic lymphocytic leukemia (CLL). It has also been found that CAL-101 has some effects on tumor microenvironment [114]. Additionally, other inhibitors targeting PI3K/AKT/mTOR, NF-κB and Wnt signaling in the clinic are listed in Table 1.

Functional involvement of non-coding RNAs in malignant hematopoiesis

Non-coding RNAs (ncRNAs), such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), play critical roles in multiple biological processes [115119]. Aberrant expression and functioning of these ncRNAs have been shown to be associated with various cancers and cancer stem cells [120125]. Here, we highlight several miRNAs and lncRNAs as key regulators in hematopoietic cells and LSCs (Fig. 1).
Fig. 1
Fig. 1

Involvement of miRNAs and lncRNAs in normal and malignant hematopoiesis. miRNAs and lncRNAs regulate almost every step of development and differentiation of hematopoietic cells during both normal and malignant hematopoiesis. Dysregulation of the ncRNAs (in red color) is associated with transformation of hematopoietic cells

Regulation of hematopoietic malignancies by miRNAs

miRNAs are 18–22 nucleotides ncRNAs that generally regulate gene expression by promoting mRNA degradation or inhibiting mRNA translation [126, 127]. During the tumorigenesis, some miRNAs act as oncogenes, whereas others function as tumor suppressors [128132]. They can regulate cell growth, proliferation, survival, migration and invasion of cancer cells. Notably, the roles of well-known miRNAs in normal and malignant hematopoiesis have been extensively reviewed [133137]. These miRNAs regulate almost every step of development and differentiation of both normal hematopoietic cells and LSCs.

MiR-125 is a highly conserved miRNA. There are three homologs of miR-125 (hsa-miR-125b-1, hsa-miR-125b-2 and hsa-miR-125a) in human [136]. Previous investigations have revealed that highly expressed miR-125 enhances self-renewal and survival of HSCs, and dysregulation of miR-125 occurs in multiple hematopoietic malignancies [138142]. In particular, miR-125 is implicated in hematopoiesis through the p53-involved regulation network [143].

Recently, Lechman and colleagues have shown that miR-126 preserves AML LSC quiescence and promotes chemotherapy resistance by targeting the PI3K/AKT/mTOR signaling pathway [144]. Interestingly, reduction of miR-126 level impairs LSC maintenance, but it plays an opposing role in normal HSCs [144]. In addition, functional involvement of miR-29a has also been found in AML LSCs [134]. Previous experiments demonstrated that miR-29a was highly expressed in AML samples. Furthermore, results exhibited that miR-29a can promote proliferation of hematopoietic progenitor, and transform AML by converting myeloid progenitors into LSCs [134].

Involvement of lncRNAs in leukemogenesis

Over the past decade, increasing numbers of lncRNAs have been identified and recognized as novel regulators that are implicated in various cellular processes. LncRNAs are generally more than 200 nucleotides in length, and modulate gene expression through interaction with DNAs, RNAs and proteins [145147]. They function at multiple levels, including gene transcription, post-transcriptional processing, RNA translation, and epigenetic modifications [148]. It has been reported that some lncRNAs are involved in the regulation of CSCs [149152]. For example, the lncRNA, named lncTCF7, has been identified to promote liver CSC self-renewal and tumor propagation by activating Wnt signaling [149]. Moreover, many lncRNAs have been seen to be associated with normal hematopoietic cells and various types of leukemia [118, 153160] (Fig. 1).

Dysregulation of lncRNA H19 has been observed in various tumors, including Bcr-Abl-induced leukemia [161164]. H19 acts as dual regulators in different cancers (either as an oncogene or a tumor suppressor) and also serves as a precursor for miR-675, known to down-regulate the tumor suppressor gene RB in human colorectal cancer [165167]. Importantly, H19 is highly expressed in long-term HSCs (LT-HSCs). H19-deficiency results in activation of the insulin-like growth factor 2 (IGF2)-IGF1 receptor pathway, leading to increased proliferation and decreased long-term self-renewal of HSCs [168].

Recently, Guo et al. have comprehensively analyzed the expression of lncRNAs in human CML cells [158]. Notably, a lncRNA termed lncRNA-BGL3 was highly induced in response to silence of Bcr-Abl expression or inhibition of Bcr-Abl kinase activity in K562 cells and leukemic cells derived from CML patients. Furthermore, lncRNA-BGL3 functions as a competitive endogenous RNA (ceRNA) to cross-regulate PTEN expression, thereby modulating leukemic cell survival. Thus, lncRNA-BGL3 has been identified as a tumor suppressor in Bcr-Abl-mediated cellular transformation.

To date, miRNAs and lncRNAs have been confirmed by increasing evidence as functional mediators in cancer cells and cancer stem cells. Some cancer-associated ncRNAs are currently considered as biomarkers for patient prognosis and potential therapeutic agents for particular cancers [128, 129, 169181]. For example, MRX34, the first miRNA mimic, entered phase I clinical trials in patients with advanced hepatocellular carcinoma in 2013 [169]. In AML, Dorrance et al. have observed that miR-126 enriches in AML LSCs and contributes to the long-term maintenance and self-renewal of LSCs. Treatment with novel nano-particles containing antagomiR-126 results in reduction of LSCs in vivo [181]. Therefore, better understanding of the mechanisms underlying functional involvement of miRNAs and lncRNAs in LSC development and leukemogenesis is of great importance for precise treatment of hematopoietic malignancies.


Over the past two decades, the function and phenotype of LSCs have been continuously defined. Furthermore, numerous studies provide accumulating evidence that there exist CSCs in a variety of solid tumors [182, 183]. Importantly, these progresses have led to the development of many novel therapeutic strategies targeting CSCs. Here, we have reviewed the current understanding of LSCs both in intrinsic and extrinsic aspects, and discussed the promising therapeutics that is being tested in clinical trials. Although identification and characterization of LSCs have renewed leukemia research and helped develop diverse clinical therapeutic strategies, some tough challenges for LSCs-based leukemia therapy still remain. One of the greatest challenges is early and efficient identification of LSCs in diverse leukemia patients. Moreover, better understanding of LSCs development and differentiation is critically required for clinical implications of the strategies targeting such cell populations. Precise mechanisms by which extracellular and intracellular molecules and their signaling regulate LSCs also remain to be determined. Therefore, further efforts are needed to identify more specific biomarkers of LSCs, determine specific targets and thereby develop efficient LSCs-based treatment of leukemia.


ABC transporters: 

ATP-binding cassette transporters


Acute myeloid leukemia

BM niche: 

Bone marrow niche


B lymphoma Mo-MLV insertion region 1 homolog

CAR T-cells: 

Chimeric antigen receptor modified T-cells


CCAAT/enhancer binding protein epsilon


CCAAT/enhancer binding protein alpha


Competitive endogenous RNA


Chronic lymphocytic leukemia


Chronic myeloid leukemia


Cancer stem cells


C-X-C motif chemokine 12


C-X-C chemokine receptor type 4


DNA methyltransferase 3 alpha


Eukaryotic translation initiation factor 4B


Food and Drug Administration


Internal tandem duplication of the gene FLT3


Hematopoietic stem cells


Isocitrate dehydrogenase 1/2


Insulin-like growth factor 2


IL-1 receptor accessory protein


Janus kinase/signal transducer and activator of transcription


Kirsten rat sarcoma viral oncogene homolog/neuroblastoma rat sarcoma viral oncogene homolog


Long non-coding RNAs


Leukemic stem cells


Long-term HSCs




mammalian/mechanistic target of rapamycin


non-coding RNAs


Nuclear factor kappa-light-chain-enhancer of activated B cells


Nucleophosmin 1


Phosphatidylinositide 3-kinase/protein kinase B


Proviral insertion in murine


Phosphatase and tensin homolog


Stromal cell derived factor-1

SOCS-1 and SOCS-3: 

suppressors of cytokine signaling 1 and 3


Tet methylcytosine dioxygenase 2


Tumor necrosis factor alpha


Vascular cell adhesion molecule 1



This work was supported by National Basic Research Program (973) of China (2014CB541804, 2015CB910502) and Natural Science Foundation of China (91640101, 81472611).

Availability of data and material

Not applicable.

Authors’ contributions

XW wrote the manuscript. J-LC and SH revised and approved the final manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Not applicable.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, 100101, China
University of Chinese Academy of Sciences, Beijing, China
Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center, Shreveport, LA, USA
College of Animal Sciences, Fujian Agriculture and Forestry University, Fuzhou, China


  1. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367:645–8.PubMedView ArticleGoogle Scholar
  2. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100:3983–8.PubMedPubMed CentralView ArticleGoogle Scholar
  3. Kim CF, Jackson EL, Woolfenden AE, et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell. 2005;121:823–35.PubMedView ArticleGoogle Scholar
  4. Burns JS, Abdallah BM, Guldberg P, et al. Tumorigenic heterogeneity in cancer stem cells evolved from long-term cultures of telomerase-immortalized human mesenchymal stem cells. Cancer Res. 2005;65:3126–35.PubMedGoogle Scholar
  5. Collins AT, Berry PA, Hyde C, et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005;65:10946–51.PubMedView ArticleGoogle Scholar
  6. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, et al. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci U S A. 2006;103:11154–9.PubMedPubMed CentralView ArticleGoogle Scholar
  7. Piccirillo SG, Reynolds BA, Zanetti N, et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature. 2006;444:761–5.PubMedView ArticleGoogle Scholar
  8. O’Brien CA, Pollett A, Gallinger S, et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007;445:106–10.PubMedView ArticleGoogle Scholar
  9. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730–7.PubMedView ArticleGoogle Scholar
  10. Bhatia M, Wang JC, Kapp U, et al. Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice. Proc Natl Acad Sci U S A. 1997;94:5320–5.PubMedPubMed CentralView ArticleGoogle Scholar
  11. Eppert K, Takenaka K, Lechman ER, et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med. 2011;17:1086–93.PubMedView ArticleGoogle Scholar
  12. Apperley JF. Chronic myeloid leukaemia. Lancet. 2015;385:1447–59.PubMedView ArticleGoogle Scholar
  13. Chen K, Huang YH, Chen JL. Understanding and targeting cancer stem cells: therapeutic implications and challenges. Acta Pharmacol Sin. 2013;34:732–40.PubMedPubMed CentralView ArticleGoogle Scholar
  14. Dohner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. N Engl J Med. 2015;373:1136–52.PubMedView ArticleGoogle Scholar
  15. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5:275–84.PubMedView ArticleGoogle Scholar
  16. Matsui W, Wang Q, Barber JP, et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res. 2008;68:190–7.PubMedPubMed CentralView ArticleGoogle Scholar
  17. Raaijmakers MH. ATP-binding-cassette transporters in hematopoietic stem cells and their utility as therapeutical targets in acute and chronic myeloid leukemia. Leukemia. 2007;21:2094–102.PubMedView ArticleGoogle Scholar
  18. Carnero A, Garcia-Mayea Y, Mir C, et al. The cancer stem-cell signaling network and resistance to therapy. Cancer Treat Rev. 2016;49:25–36.PubMedView ArticleGoogle Scholar
  19. Lane SW, Gilliland DG. Leukemia stem cells. Semin Cancer Biol. 2010;20:71–6.PubMedView ArticleGoogle Scholar
  20. Ley TJ, Mardis ER, Ding L, et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature. 2008;456:66–72.PubMedPubMed CentralView ArticleGoogle Scholar
  21. Abdel-Wahab O, Mullally A, Hedvat C, et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood. 2009;114:144–7.PubMedPubMed CentralView ArticleGoogle Scholar
  22. Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009;361:1058–66.PubMedPubMed CentralView ArticleGoogle Scholar
  23. Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363:2424–33.PubMedPubMed CentralView ArticleGoogle Scholar
  24. Ernst T, Chase AJ, Score J, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet. 2010;42:722–6.PubMedView ArticleGoogle Scholar
  25. Nikoloski G, Langemeijer SM, Kuiper RP, et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet. 2010;42:665–7.PubMedView ArticleGoogle Scholar
  26. Greif PA, Eck SH, Konstandin NP, et al. Identification of recurring tumor-specific somatic mutations in acute myeloid leukemia by transcriptome sequencing. Leukemia. 2011;25:821–7.PubMedView ArticleGoogle Scholar
  27. Yan XJ, Xu J, Gu ZH, et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet. 2011;43:309–15.PubMedView ArticleGoogle Scholar
  28. Cancer Genome Atlas Research N. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368:2059–74.View ArticleGoogle Scholar
  29. Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012;481:506–10.PubMedPubMed CentralView ArticleGoogle Scholar
  30. Kronke J, Bullinger L, Teleanu V, et al. Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. Blood. 2013;122:100–8.PubMedView ArticleGoogle Scholar
  31. Li S, Garrett-Bakelman F, Perl AE, et al. Dynamic evolution of clonal epialleles revealed by methclone. Genome Biol. 2014;15:472.PubMedPubMed CentralView ArticleGoogle Scholar
  32. Welch JS, Ley TJ, Link DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012;150:264–78.PubMedPubMed CentralView ArticleGoogle Scholar
  33. Shlush LI, Zandi S, Mitchell A, et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature. 2014;506:328–33.PubMedPubMed CentralView ArticleGoogle Scholar
  34. Xie M, Lu C, Wang J, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med. 2014;20:1472–8.PubMedPubMed CentralView ArticleGoogle Scholar
  35. Corces-Zimmerman MR, Hong WJ, Weissman IL, et al. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci U S A. 2014;111:2548–53.PubMedPubMed CentralView ArticleGoogle Scholar
  36. Gerber JM, Gucwa JL, Esopi D, et al. Genome-wide comparison of the transcriptomes of highly enriched normal and chronic myeloid leukemia stem and progenitor cell populations. Oncotarget. 2013;4:715–28.PubMedPubMed CentralView ArticleGoogle Scholar
  37. Blair A, Hogge DE, Ailles LE, et al. Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo. Blood. 1997;89:3104–12.PubMedGoogle Scholar
  38. Blair A, Hogge DE, Sutherland HJ. Most acute myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34(+)/CD71(−)/HLA-DR. Blood. 1998;92:4325–35.PubMedGoogle Scholar
  39. Blair A, Sutherland HJ. Primitive acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo lack surface expression of c-kit (CD117). Exp Hematol. 2000;28:660–71.PubMedView ArticleGoogle Scholar
  40. Jordan CT, Upchurch D, Szilvassy SJ, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000;14:1777–84.PubMedView ArticleGoogle Scholar
  41. Taussig DC, Miraki-Moud F, Anjos-Afonso F, et al. Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood. 2008;112:568–75.PubMedView ArticleGoogle Scholar
  42. Jin L, Lee EM, Ramshaw HS, et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell. 2009;5:31–42.PubMedView ArticleGoogle Scholar
  43. Taussig DC, Vargaftig J, Miraki-Moud F, et al. Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(−) fraction. Blood. 2010;115:1976–84.PubMedPubMed CentralView ArticleGoogle Scholar
  44. Kikushige Y, Shima T, Takayanagi S, et al. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell. 2010;7:708–17.PubMedView ArticleGoogle Scholar
  45. Sarry JE, Murphy K, Perry R, et al. Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rgammac-deficient mice. J Clin Invest. 2011;121:384–95.PubMedView ArticleGoogle Scholar
  46. Hope KJ, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol. 2004;5:738–43.PubMedView ArticleGoogle Scholar
  47. Moshaver B, van Rhenen A, Kelder A, et al. Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia. Stem Cells. 2008;26:3059–67.PubMedView ArticleGoogle Scholar
  48. Busfield SJ, Biondo M, Wong M, et al. Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC. Leukemia. 2014;28:2213–21.PubMedView ArticleGoogle Scholar
  49. Jan M, Chao MP, Cha AC, et al. Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. Proc Natl Acad Sci U S A. 2011;108:5009–14.PubMedPubMed CentralView ArticleGoogle Scholar
  50. Jaiswal S, Jamieson CH, Pang WW, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 2009;138:271–85.PubMedPubMed CentralView ArticleGoogle Scholar
  51. Majeti R, Chao MP, Alizadeh AA, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009;138:286–99.PubMedPubMed CentralView ArticleGoogle Scholar
  52. Hosen N, Park CY, Tatsumi N, et al. CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc Natl Acad Sci U S A. 2007;104:11008–13.PubMedPubMed CentralView ArticleGoogle Scholar
  53. van Rhenen A, van Dongen GA, Kelder A, et al. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood. 2007;110:2659–66.PubMedView ArticleGoogle Scholar
  54. Zhao X, Singh S, Pardoux C, et al. Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia. Haematologica. 2010;95:71–8.PubMedView ArticleGoogle Scholar
  55. Askmyr M, Agerstam H, Hansen N, et al. Selective killing of candidate AML stem cells by antibody targeting of IL1RAP. Blood. 2013;121:3709–13.PubMedView ArticleGoogle Scholar
  56. Weiskopf K, Ring AM, Ho CC, et al. Engineered SIRPalpha variants as immunotherapeutic adjuvants to anticancer antibodies. Science. 2013;341:88–91.PubMedView ArticleGoogle Scholar
  57. Theocharides AP, Jin L, Cheng PY, et al. Disruption of SIRPalpha signaling in macrophages eliminates human acute myeloid leukemia stem cells in xenografts. J Exp Med. 2012;209:1883–99.PubMedPubMed CentralView ArticleGoogle Scholar
  58. Mohseni Nodehi S, Repp R, Kellner C, et al. Enhanced ADCC activity of affinity maturated and Fc-engineered mini-antibodies directed against the AML stem cell antigen CD96. PLoS One. 2012;7:e42426.PubMedPubMed CentralView ArticleGoogle Scholar
  59. Bakker AB, van den Oudenrijn S, Bakker AQ, et al. C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia. Cancer Res. 2004;64:8443–50.PubMedView ArticleGoogle Scholar
  60. Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001;7:1490–6.PubMedGoogle Scholar
  61. Majeti R. Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells. Oncogene. 2011;30:1009–19.PubMedView ArticleGoogle Scholar
  62. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol. 2010;10:317–27.PubMedPubMed CentralView ArticleGoogle Scholar
  63. Kuo SR, Wong L, Liu JS. Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells. Protein Eng Des Sel. 2012;25:561–9.PubMedView ArticleGoogle Scholar
  64. Kugler M, Stein C, Kellner C, et al. A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting. Br J Haematol. 2010;150:574–86.PubMedView ArticleGoogle Scholar
  65. Frankel A, Liu JS, Rizzieri D, et al. Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia. Leuk Lymphoma. 2008;49:543–53.PubMedView ArticleGoogle Scholar
  66. Tettamanti S, Marin V, Pizzitola I, et al. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor. Br J Haematol. 2013;161:389–401.PubMedView ArticleGoogle Scholar
  67. Kievit FM, Zhang M. Cancer nanotheranostics: improving imaging and therapy by targeted delivery across biological barriers. Adv Mater. 2011;23:H217–47.PubMedPubMed CentralView ArticleGoogle Scholar
  68. Schepers K, Campbell TB, Passegue E. Normal and leukemic stem cell niches: insights and therapeutic opportunities. Cell Stem Cell. 2015;16:254–67.PubMedPubMed CentralView ArticleGoogle Scholar
  69. Colmone A, Amorim M, Pontier AL, et al. Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science. 2008;322:1861–5.PubMedView ArticleGoogle Scholar
  70. Roboz GJ, Guzman M. Acute myeloid leukemia stem cells: seek and destroy. Expert Rev Hematol. 2009;2:663–72.PubMedView ArticleGoogle Scholar
  71. Konopleva MY, Jordan CT. Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol. 2011;29:591–9.PubMedPubMed CentralView ArticleGoogle Scholar
  72. Perry JM, Li L. Disrupting the stem cell niche: good seeds in bad soil. Cell. 2007;129:1045–7.PubMedView ArticleGoogle Scholar
  73. Zhang J, Niu C, Ye L, et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature. 2003;425:836–41.PubMedView ArticleGoogle Scholar
  74. Spoo AC, Lubbert M, Wierda WG, et al. CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood. 2007;109:786–91.PubMedView ArticleGoogle Scholar
  75. Uy GL, Rettig MP, Motabi IH, et al. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood. 2012;119:3917–24.PubMedPubMed CentralView ArticleGoogle Scholar
  76. Broxmeyer HE, Orschell CM, Clapp DW, et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med. 2005;201:1307–18.PubMedPubMed CentralView ArticleGoogle Scholar
  77. Mohty M, Duarte RF, Croockewit S, et al. The role of plerixafor in optimizing peripheral blood stem cell mobilization for autologous stem cell transplantation. Leukemia. 2011;25:1–6.PubMedView ArticleGoogle Scholar
  78. Nervi B, Ramirez P, Rettig MP, et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood. 2009;113:6206–14.PubMedPubMed CentralView ArticleGoogle Scholar
  79. Krause DS, Lazarides K, von Andrian UH, et al. Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat Med. 2006;12:1175–80.PubMedView ArticleGoogle Scholar
  80. Jacamo R, Chen Y, Wang Z, et al. Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-kappaB mediates chemoresistance. Blood. 2014;123:2691–702.PubMedPubMed CentralView ArticleGoogle Scholar
  81. Schepers K, Pietras EM, Reynaud D, et al. Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche. Cell Stem Cell. 2013;13:285–99.PubMedPubMed CentralView ArticleGoogle Scholar
  82. Chan WI, Huntly BJ. Leukemia stem cells in acute myeloid leukemia. Semin Oncol. 2008;35:326–35.PubMedView ArticleGoogle Scholar
  83. Zhao C, Blum J, Chen A, et al. Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell. 2007;12:528–41.PubMedPubMed CentralView ArticleGoogle Scholar
  84. Hu Y, Chen Y, Douglas L, et al. beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia. Leukemia. 2009;23:109–16.PubMedView ArticleGoogle Scholar
  85. Wang Y, Krivtsov AV, Sinha AU, et al. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science. 2010;327:1650–3.PubMedPubMed CentralView ArticleGoogle Scholar
  86. Yeung J, Esposito MT, Gandillet A, et al. beta-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell. 2010;18:606–18.PubMedView ArticleGoogle Scholar
  87. Griffiths EA, Gore SD, Hooker C, et al. Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation. Leuk Lymphoma. 2010;51:1711–9.PubMedPubMed CentralView ArticleGoogle Scholar
  88. Gandillet A, Park S, Lassailly F, et al. Heterogeneous sensitivity of human acute myeloid leukemia to beta-catenin down-modulation. Leukemia. 2011;25:770–80.PubMedPubMed CentralView ArticleGoogle Scholar
  89. Siapati EK, Papadaki M, Kozaou Z, et al. Proliferation and bone marrow engraftment of AML blasts is dependent on beta-catenin signalling. Br J Haematol. 2011;152:164–74.PubMedView ArticleGoogle Scholar
  90. Dierks C, Beigi R, Guo GR, et al. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell. 2008;14:238–49.PubMedView ArticleGoogle Scholar
  91. Zhao C, Chen A, Jamieson CH, et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature. 2009;458:776–9.PubMedPubMed CentralView ArticleGoogle Scholar
  92. Jagani Z, Dorsch M, Warmuth M. Hedgehog pathway activation in chronic myeloid leukemia. Cell Cycle. 2010;9:3449–56.PubMedView ArticleGoogle Scholar
  93. Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105–11.PubMedView ArticleGoogle Scholar
  94. Guzman ML, Neering SJ, Upchurch D, et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood. 2001;98:2301–7.PubMedView ArticleGoogle Scholar
  95. Guzman ML, Rossi RM, Karnischky L, et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood. 2005;105:4163–9.PubMedPubMed CentralView ArticleGoogle Scholar
  96. Costello RT, Mallet F, Gaugler B, et al. Human acute myeloid leukemia CD34+/CD38-progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. Cancer Res. 2000;60:4403–11.PubMedGoogle Scholar
  97. Reya T, Duncan AW, Ailles L, et al. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature. 2003;423:409–14.PubMedView ArticleGoogle Scholar
  98. Li VS, Ng SS, Boersema PJ, et al. Wnt signaling through inhibition of beta-catenin degradation in an intact Axin1 complex. Cell. 2012;149:1245–56.PubMedView ArticleGoogle Scholar
  99. Cobas M, Wilson A, Ernst B, et al. Beta-catenin is dispensable for hematopoiesis and lymphopoiesis. J Exp Med. 2004;199:221–9.PubMedPubMed CentralView ArticleGoogle Scholar
  100. Jeannet G, Scheller M, Scarpellino L, et al. Long-term, multilineage hematopoiesis occurs in the combined absence of beta-catenin and gamma-catenin. Blood. 2008;111:142–9.PubMedView ArticleGoogle Scholar
  101. Staal FJ, Clevers HC. WNT signalling and haematopoiesis: a WNT-WNT situation. Nat Rev Immunol. 2005;5:21–30.PubMedView ArticleGoogle Scholar
  102. Duchartre Y, Kim YM, Kahn M. The Wnt signaling pathway in cancer. Crit Rev Oncol Hematol. 2016;99:141–9.PubMedView ArticleGoogle Scholar
  103. Lessard J, Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature. 2003;423:255–60.PubMedView ArticleGoogle Scholar
  104. Park IK, Qian D, Kiel M, et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature. 2003;423:302–5.PubMedView ArticleGoogle Scholar
  105. Schuringa JJ, Vellenga E. Role of the polycomb group gene BMI1 in normal and leukemic hematopoietic stem and progenitor cells. Curr Opin Hematol. 2010;17:294–9.PubMedView ArticleGoogle Scholar
  106. Faderl S, Talpaz M, Estrov Z, et al. The biology of chronic myeloid leukemia. N Engl J Med. 1999;341:164–72.PubMedView ArticleGoogle Scholar
  107. Quintas-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood. 2009;113:1619–30.PubMedPubMed CentralView ArticleGoogle Scholar
  108. Chen JL, Limnander A, Rothman PB. Pim-1 and Pim-2 kinases are required for efficient pre-B-cell transformation by v-Abl oncogene. Blood. 2008;111:1677–85.PubMedView ArticleGoogle Scholar
  109. Qiu X, Guo G, Chen K, et al. A requirement for SOCS-1 and SOCS-3 phosphorylation in Bcr-Abl-induced tumorigenesis. Neoplasia. 2012;14:547–58.PubMedPubMed CentralView ArticleGoogle Scholar
  110. Guo G, Qiu X, Wang S, et al. Oncogenic E17K mutation in the pleckstrin homology domain of AKT1 promotes v-Abl-mediated pre-B-cell transformation and survival of Pim-deficient cells. Oncogene. 2010;29:3845–53.PubMedView ArticleGoogle Scholar
  111. Gutierrez A, Sanda T, Grebliunaite R, et al. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood. 2009;114:647–50.PubMedPubMed CentralView ArticleGoogle Scholar
  112. Yang J, Wang J, Chen K, et al. eIF4B phosphorylation by pim kinases plays a critical role in cellular transformation by Abl oncogenes. Cancer Res. 2013;73:4898–908.PubMedView ArticleGoogle Scholar
  113. Chen K, Yang J, Li J, et al. eIF4B is a convergent target and critical effector of oncogenic Pim and PI3K/Akt/mTOR signaling pathways in Abl transformants. Oncotarget. 2016;7:10073–89.PubMedPubMed CentralGoogle Scholar
  114. Fruman DA, Rommel C. PI3Kdelta inhibitors in cancer: rationale and serendipity merge in the clinic. Cancer Discov. 2011;1:562–72.PubMedView ArticleGoogle Scholar
  115. Paralkar VR, Weiss MJ. Long noncoding RNAs in biology and hematopoiesis. Blood. 2013;121:4842–6.PubMedPubMed CentralView ArticleGoogle Scholar
  116. Ng SY, Lin L, Soh BS, et al. Long noncoding RNAs in development and disease of the central nervous system. Trends Genet. 2013;29:461–8.PubMedView ArticleGoogle Scholar
  117. Atianand MK, Fitzgerald KA. Long non-coding RNAs and control of gene expression in the immune system. Trends Mol Med. 2014;20:623–31.PubMedPubMed CentralView ArticleGoogle Scholar
  118. Satpathy AT, Chang HY. Long noncoding RNA in hematopoiesis and immunity. Immunity. 2015;42:792–804.PubMedView ArticleGoogle Scholar
  119. Ouyang J, Zhu X, Chen Y, et al. NRAV, a long noncoding RNA, modulates antiviral responses through suppression of interferon-stimulated gene transcription. Cell Host Microbe. 2014;16:616–26.PubMedView ArticleGoogle Scholar
  120. Undi RB, Kandi R, Gutti RK. MicroRNAs as Haematopoiesis Regulators. Adv Hematol. 2013;2013:695754.PubMedPubMed CentralView ArticleGoogle Scholar
  121. Croce CM. MicroRNA dysregulation in acute myeloid leukemia. J Clin Oncol. 2013;31:2065–6.PubMedView ArticleGoogle Scholar
  122. Machova Polakova K, Lopotova T, Klamova H, et al. Expression patterns of microRNAs associated with CML phases and their disease related targets. Mol Cancer. 2011;10:41.PubMedPubMed CentralView ArticleGoogle Scholar
  123. Wapinski O, Chang HY. Long noncoding RNAs and human disease. Trends Cell Biol. 2011;21:354–61.PubMedView ArticleGoogle Scholar
  124. Martens-Uzunova ES, Bottcher R, Croce CM, et al. Long noncoding RNA in prostate, bladder, and kidney cancer. Eur Urol. 2014;65:1140–51.PubMedView ArticleGoogle Scholar
  125. Takahashi K, Yan I, Haga H, et al. Long noncoding RNA in liver diseases. Hepatology. 2014;60:744–53.PubMedPubMed CentralView ArticleGoogle Scholar
  126. Lin S, Gregory RI. MicroRNA biogenesis pathways in cancer. Nat Rev Cancer. 2015;15:321–33.PubMedPubMed CentralView ArticleGoogle Scholar
  127. Gregory RI, Shiekhattar R. MicroRNA biogenesis and cancer. Cancer Res. 2005;65:3509–12.PubMedView ArticleGoogle Scholar
  128. Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med. 2014;20:460–9.PubMedView ArticleGoogle Scholar
  129. Ling H, Fabbri M, Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov. 2013;12:847–65.PubMedPubMed CentralView ArticleGoogle Scholar
  130. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259–69.PubMedView ArticleGoogle Scholar
  131. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6:857–66.PubMedView ArticleGoogle Scholar
  132. Nicoloso MS, Spizzo R, Shimizu M, et al. MicroRNAs-the micro steering wheel of tumour metastases. Nat Rev Cancer. 2009;9:293–302.PubMedView ArticleGoogle Scholar
  133. Yendamuri S, Calin GA. The role of microRNA in human leukemia: a review. Leukemia. 2009;23:1257–63.PubMedView ArticleGoogle Scholar
  134. Han YC, Park CY, Bhagat G, et al. microRNA-29a induces aberrant self-renewal capacity in hematopoietic progenitors, biased myeloid development, and acute myeloid leukemia. J Exp Med. 2010;207:475–89.PubMedPubMed CentralView ArticleGoogle Scholar
  135. Zimmerman AL, Wu S. MicroRNAs, cancer and cancer stem cells. Cancer Lett. 2011;300:10–9.PubMedView ArticleGoogle Scholar
  136. Shaham L, Binder V, Gefen N, et al. MiR-125 in normal and malignant hematopoiesis. Leukemia. 2012;26:2011–8.PubMedView ArticleGoogle Scholar
  137. Morris VA, Zhang A, Yang T, et al. MicroRNA-150 expression induces myeloid differentiation of human acute leukemia cells and normal hematopoietic progenitors. PLoS One. 2013;8:e75815.PubMedPubMed CentralView ArticleGoogle Scholar
  138. Enomoto Y, Kitaura J, Hatakeyama K, et al. Emu/miR-125b transgenic mice develop lethal B-cell malignancies. Leukemia. 2011;25:1849–56.PubMedView ArticleGoogle Scholar
  139. Chapiro E, Russell LJ, Struski S, et al. A new recurrent translocation t(11;14)(q24;q32) involving IGH@ and miR-125b-1 in B-cell progenitor acute lymphoblastic leukemia. Leukemia. 2010;24:1362–4.PubMedView ArticleGoogle Scholar
  140. Klusmann JH, Li Z, Bohmer K, et al. miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia. Genes Dev. 2010;24:478–90.PubMedPubMed CentralView ArticleGoogle Scholar
  141. Bousquet M, Quelen C, Rosati R, et al. Myeloid cell differentiation arrest by miR-125b-1 in myelodysplastic syndrome and acute myeloid leukemia with the t(2;11)(p21;q23) translocation. J Exp Med. 2008;205:2499–506.PubMedPubMed CentralView ArticleGoogle Scholar
  142. Zhou Y, Chen L, Barlogie B, et al. High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2. Proc Natl Acad Sci U S A. 2010;107:7904–9.PubMedPubMed CentralView ArticleGoogle Scholar
  143. Tarasov V, Jung P, Verdoodt B, et al. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle. 2007;6:1586–93.PubMedView ArticleGoogle Scholar
  144. Lechman ER, Gentner B, Ng SW, et al. miR-126 Regulates Distinct Self-Renewal Outcomes in Normal and Malignant Hematopoietic Stem Cells. Cancer Cell. 2016;29:214–28.PubMedPubMed CentralView ArticleGoogle Scholar
  145. Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009;10:155–9.PubMedView ArticleGoogle Scholar
  146. Wilusz JE, Sunwoo H, Spector DL. Long noncoding RNAs: functional surprises from the RNA world. Genes Dev. 2009;23:1494–504.PubMedPubMed CentralView ArticleGoogle Scholar
  147. Bonasio R, Shiekhattar R. Regulation of transcription by long noncoding RNAs. Annu Rev Genet. 2014;48:433–55.PubMedPubMed CentralView ArticleGoogle Scholar
  148. Mercer TR, Mattick JS. Structure and function of long noncoding RNAs in epigenetic regulation. Nat Struct Mol Biol. 2013;20:300–7.PubMedView ArticleGoogle Scholar
  149. Wang Y, He L, Du Y, et al. The long noncoding RNA lncTCF7 promotes self-renewal of human liver cancer stem cells through activation of Wnt signaling. Cell Stem Cell. 2015;16:413–25.PubMedView ArticleGoogle Scholar
  150. Zhu P, Wang Y, Huang G, et al. lnc-beta-Catm elicits EZH2-dependent beta-catenin stabilization and sustains liver CSC self-renewal. Nat Struct Mol Biol. 2016;23:631–9.PubMedView ArticleGoogle Scholar
  151. Wang X, Sun W, Shen W, et al. Long non-coding RNA DILC regulates liver cancer stem cells via IL-6/STAT3 axis. J Hepatol. 2016;64:1283–94.PubMedView ArticleGoogle Scholar
  152. Zhou X, Gao Q, Wang J, et al. Linc-RNA-RoR acts as a “sponge” against mediation of the differentiation of endometrial cancer stem cells by microRNA-145. Gynecol Oncol. 2014;133:333–9.PubMedView ArticleGoogle Scholar
  153. Sehgal L, Mathur R, Braun FK, et al. FAS-antisense 1 lncRNA and production of soluble versus membrane Fas in B-cell lymphoma. Leukemia. 2014;28:2376–87.PubMedView ArticleGoogle Scholar
  154. Trimarchi T, Bilal E, Ntziachristos P, et al. Genome-wide mapping and characterization of Notch-regulated long noncoding RNAs in acute leukemia. Cell. 2014;158:593–606.PubMedPubMed CentralView ArticleGoogle Scholar
  155. Sun J, Li W, Sun Y, et al. A novel antisense long noncoding RNA within the IGF1R gene locus is imprinted in hematopoietic malignancies. Nucleic Acids Res. 2014;42:9588–601.PubMedPubMed CentralView ArticleGoogle Scholar
  156. Hughes JM, Legnini I, Salvatori B, et al. C/EBPalpha-p30 protein induces expression of the oncogenic long non-coding RNA UCA1 in acute myeloid leukemia. Oncotarget. 2015;6:18534–44.PubMedPubMed CentralView ArticleGoogle Scholar
  157. Wang X, Chen K, Guo G, et al. Noncoding RNAs and their functional involvement in regulation of chronic myeloid leukemia. Brief Funct Genomics. 2016;15:239–48.PubMedView ArticleGoogle Scholar
  158. Guo G, Kang Q, Zhu X, et al. A long noncoding RNA critically regulates Bcr-Abl-mediated cellular transformation by acting as a competitive endogenous RNA. Oncogene. 2015;34:1768–79.PubMedView ArticleGoogle Scholar
  159. Nobili L, Lionetti M, Neri A. Long non-coding RNAs in normal and malignant hematopoiesis. Oncotarget. 2016.Google Scholar
  160. Luo M, Jeong M, Sun D, et al. Long non-coding RNAs control hematopoietic stem cell function. Cell Stem Cell. 2015;16:426–38.PubMedPubMed CentralView ArticleGoogle Scholar
  161. Tanos V, Ariel I, Prus D, et al. H19 and IGF2 gene expression in human normal, hyperplastic, and malignant endometrium. Int J Gynecol Cancer. 2004;14:521–5.PubMedView ArticleGoogle Scholar
  162. Yoshimizu T, Miroglio A, Ripoche MA, et al. The H19 locus acts in vivo as a tumor suppressor. Proc Natl Acad Sci U S A. 2008;105:12417–22.PubMedPubMed CentralView ArticleGoogle Scholar
  163. Gabory A, Jammes H, Dandolo L. The H19 locus: role of an imprinted non-coding RNA in growth and development. Bioessays. 2010;32:473–80.PubMedView ArticleGoogle Scholar
  164. Guo G, Kang Q, Chen Q, et al. High expression of long non-coding RNA H19 is required for efficient tumorigenesis induced by Bcr-Abl oncogene. FEBS Lett. 2014;588:1780–6.PubMedView ArticleGoogle Scholar
  165. Tsang WP, Ng EK, Ng SS, et al. Oncofetal H19-derived miR-675 regulates tumor suppressor RB in human colorectal cancer. Carcinogenesis. 2010;31:350–8.PubMedView ArticleGoogle Scholar
  166. Cai X, Cullen BR. The imprinted H19 noncoding RNA is a primary microRNA precursor. RNA. 2007;13:313–6.PubMedPubMed CentralView ArticleGoogle Scholar
  167. Keniry A, Oxley D, Monnier P, et al. The H19 lincRNA is a developmental reservoir of miR-675 that suppresses growth and Igf1r. Nat Cell Biol. 2012;14:659–65.PubMedPubMed CentralView ArticleGoogle Scholar
  168. Venkatraman A, He XC, Thorvaldsen JL, et al. Maternal imprinting at the H19-Igf2 locus maintains adult haematopoietic stem cell quiescence. Nature. 2013;500:345–9.PubMedPubMed CentralView ArticleGoogle Scholar
  169. Bouchie A. First microRNA mimic enters clinic. Nat Biotechnol. 2013;31:577.PubMedView ArticleGoogle Scholar
  170. Ren S, Wang F, Shen J, et al. Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer. Eur J Cancer. 2013;49:2949–59.PubMedView ArticleGoogle Scholar
  171. Crea F, Watahiki A, Quagliata L, et al. Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer. Oncotarget. 2014;5:764–74.PubMedPubMed CentralView ArticleGoogle Scholar
  172. Wahlestedt C. Targeting long non-coding RNA to therapeutically upregulate gene expression. Nat Rev Drug Discov. 2013;12:433–46.PubMedView ArticleGoogle Scholar
  173. Sun J, Song Y, Chen X, et al. Novel long non-coding RNA RP11-119 F7.4 as a potential biomarker for the development and progression of gastric cancer. Oncol Lett. 2015;10:115–20.PubMedPubMed CentralGoogle Scholar
  174. Zhou X, Yin C, Dang Y, et al. Identification of the long non-coding RNA H19 in plasma as a novel biomarker for diagnosis of gastric cancer. Sci Rep. 2015;5:11516.PubMedPubMed CentralView ArticleGoogle Scholar
  175. Qiu JJ, Yan JB. Long non-coding RNA LINC01296 is a potential prognostic biomarker in patients with colorectal cancer. Tumour Biol. 2015;36:7175–83.PubMedView ArticleGoogle Scholar
  176. Tong X, Gu PC, Xu SZ, et al. Long non-coding RNA-DANCR in human circulating monocytes: a potential biomarker associated with postmenopausal osteoporosis. Biosci Biotechnol Biochem. 2015;79:732–7.PubMedView ArticleGoogle Scholar
  177. Tong YS, Wang XW, Zhou XL, et al. Identification of the long non-coding RNA POU3F3 in plasma as a novel biomarker for diagnosis of esophageal squamous cell carcinoma. Mol Cancer. 2015;14:3.PubMedPubMed CentralView ArticleGoogle Scholar
  178. Meng L, Ward AJ, Chun S, et al. Towards a therapy for Angelman syndrome by targeting a long non-coding RNA. Nature. 2015;518:409–12.PubMedView ArticleGoogle Scholar
  179. Yang Y, Cai Y, Wu G, et al. Plasma long non-coding RNA, CoroMarker, a novel biomarker for diagnosis of coronary artery disease. Clin Sci (Lond). 2015;129:675–85.View ArticleGoogle Scholar
  180. Velu CS, Chaubey A, Phelan JD, et al. Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity. J Clin Invest. 2014;124:222–36.PubMedView ArticleGoogle Scholar
  181. Dorrance AM, Neviani P, Ferenchak GJ, et al. Targeting leukemia stem cells in vivo with antagomiR-126 nanoparticles in acute myeloid leukemia. Leukemia. 2015;29:2143–53.PubMedPubMed CentralGoogle Scholar
  182. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008;8:755–68.PubMedView ArticleGoogle Scholar
  183. Wang JC, Dick JE. Cancer stem cells: lessons from leukemia. Trends Cell Biol. 2005;15:494–501.PubMedView ArticleGoogle Scholar
  184. Papa V, Tazzari PL, Chiarini F, et al. Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells. Leukemia. 2008;22:147–60.PubMedView ArticleGoogle Scholar
  185. Tazzari PL, Tabellini G, Ricci F, et al. Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells. Cancer Res. 2008;68:9394–403.PubMedPubMed CentralView ArticleGoogle Scholar
  186. Konopleva MY, Walter RB, Faderl SH, et al. Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia. Clin Cancer Res. 2014;20:2226–35.PubMedPubMed CentralView ArticleGoogle Scholar
  187. Sandhofer N, Metzeler KH, Rothenberg M, et al. Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia. Leukemia. 2015;29:828–38.PubMedView ArticleGoogle Scholar
  188. Park S, Chapuis N, Saint Marcoux F, et al. A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse. Leukemia. 2013;27:1479–86.PubMedView ArticleGoogle Scholar
  189. Chiarini F, Lonetti A, Teti G, et al. A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia. Oncotarget. 2012;3:1615–28.PubMedPubMed CentralView ArticleGoogle Scholar
  190. Amadori S, Stasi R, Martelli AM, et al. Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107). Br J Haematol. 2012;156:205–12.PubMedView ArticleGoogle Scholar
  191. Attar EC, Amrein PC, Fraser JW, et al. Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Leuk Res. 2013;37:1016–20.PubMedPubMed CentralView ArticleGoogle Scholar
  192. Horton TM, Perentesis JP, Gamis AS, et al. A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2014;61:1754–60.PubMedPubMed CentralView ArticleGoogle Scholar
  193. Zeng Z, Shi YX, Samudio IJ, et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood. 2009;113:6215–24.PubMedPubMed CentralView ArticleGoogle Scholar


© The Author(s). 2017